STOCKHOLM, June 10, 2026 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of AI-powered skin health solutions, today announced that the first...
TORONTO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and nine months ended June 30, 2025 and provided an update on its business.
The vitiligo market is witnessing steady growth due to rising disease awareness, improved diagnostic capabilities, and advancements in treatment options such as JAK inhibitors...
The interleukin-17 inhibitors market is expected to remain strong in rheumatology (psoriasis and arthritis), with potential expansion into hidradenitis suppurativa and other dermatologic conditions....
The interleukin-17 inhibitors market is expected to remain strong in rheumatology (psoriasis and arthritis), with potential expansion into hidradenitis suppurativa and other dermatologic conditions....